Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06902519 · ClinicalTrials.gov registry record · Phase 1
Study of GS-0151 in Participants With Rheumatoid Arthritis
A Phase 1 study of Rheumatoid Arthritis, sponsored by Gilead Sciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 20
- Study locations
NCT06902519: Recruiting Phase 1 study of Rheumatoid Arthritis, sponsored by Gilead Sciences.
NCT06902519 is a Phase 1 study of Rheumatoid Arthritis that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 75 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06902519, a Phase 1 study of Rheumatoid Arthritis, is actively recruiting participants, sponsored by Gilead Sciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical study is to learn more about the study drug GS-0151. The study is done to find how safe, well-tolerated the drug is. This will also assess how the drug is absorbed, modified, distributed and cleared from the body (the pharmacokinetics (PK) of the drug), when given multiple times to participants with rheumatoid arthritis (RA). The primary objectives of this study is to assess the safety and tolerability of multiple ascending doses of GS-0151 in participants with RA and to characterize the PK of GS-0151 following multiple doses of GS-0151 in participants with RA.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GS-0151
Study Locations (20)
Other
- ARENSIA Exploratory Medicine, LLC - Tbilisi
- Universitatsklinikum Koln - Cologne
- Krakenhaus Porz am Rhein - Cologne
- Hamburger Rheuma Forschungszentrum II - Hamburg
- Klinikum der Universitat Munchen - München
California
- University of California, San Diego - La Jolla
- Stanford University School of Medicine - Palo Alto
- Medvin Clinical Research - Tujunga
- Medvin Clinical Research - Whittier
Texas
- Accurate Clinical Management, LLC - Baytown
- Accurate Clinical Research, Inc - Houston
- Clinical Trials of Texas LLC, dba Flourish Research - San Antonio
Illinois
- Great Lakes Clinical Trials dba Flourish Research Chicago - Chicago
- DM Clinical Research - Melrose Park
Alabama
- Pinnacle Research Group, LLC - Anniston
Florida
- Clinical Research of West Florida, Inc - Clearwater
Louisiana
- Accurate Clinical Research, Inc - Lake Charles
Oklahoma
- Lynn Health Science Institute - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-05-14 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
What NCT06902519 shows while recruiting
NCT06902519 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06902519 names 20 study sites across 10 states, led by Other, California, Texas.
Frequently Asked Questions
What is clinical trial NCT06902519 about?
NCT06902519 is a clinical study titled "Study of GS-0151 in Participants With Rheumatoid Arthritis". The goal of this clinical study is to learn more about the study drug GS-0151. The study is done to find how safe, well-tolerated the drug is. This will also assess how the drug is absorbed, modified, distributed and cleared from the body (the pharmacokinetics (PK) of the drug), when given multiple ...
What is the current status of trial NCT06902519?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2025-05-14. Estimated completion is 2027-03.
What conditions does trial NCT06902519 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT06902519?
The interventions under investigation include: Placebo (DRUG), GS-0151 (DRUG).
Who is sponsoring clinical trial NCT06902519?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06902519 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06902519's enrollment target sits among peer trials
75 126th of 197 higher than 69 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
MAD Study of IA-14069
RECRUITING · Phase 1
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
RECRUITING · Phase 1
-
Imaging of Lymphatic Vessels in People with Rheumatoid Arthritis (RA)
RECRUITING · Phase 1
-
Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI